Nanomedicine faces barriers

Pharmaceuticals

Volumn 3, Issue 11, 2010, Pages 3371-3416

  Debbage, Paul ^a   Thurner, Gudrun C ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Central nervous tissues; Glandular tissues; Lesion specific targeting; Nanomedicine; Transbarrier targeting; Vascular barriers

Indexed keywords

NANOPARTICLE; PACLITAXEL;

ATHEROSCLEROSIS; BASEMENT MEMBRANE; BLOOD BRAIN BARRIER; BLOOD MILK BARRIER; BLOOD TISSUE BARRIER; BLOOD VESSEL PERMEABILITY; CELL SURFACE; DIFFUSION; DRUG PENETRATION; DRUG TARGETING; DRUG TRANSPORT; ENDOCYTOSIS; EXTRACELLULAR MATRIX; GOOD MANUFACTURING PRACTICE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; IMMUNOTHERAPY; MECHANICAL TORSION; MOLECULARLY TARGETED THERAPY; NANOMEDICINE; NANOPHARMACEUTICS; NONHUMAN; NOSE MUCOSA; OLFACTORY EPITHELIUM; PARTICLE SIZE; PERMEABILITY BARRIER; PROGNOSIS; REVIEW; TIGHT JUNCTION; TRANSCYTOSIS; VASCULAR ENDOTHELIUM;

EID: 78650313915     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3113371     Document Type: Review

References (316)

1. Ehrlich, P. On immunity with special reference to cell life. Proc. R. Soc. 1900, 66, 424-448.
2. Stumpf, W.E. The dose makes the medicine. Drug Dis. Today 2006, 11, 550-555.
3. Evans, W.E.; Pratt, C.B.; Taylor, R.H.; Barker, L.F.; Crom, W.R. Pharmacokinetic monitoring of high-dose methotrexate. Cancer Chemother. Pharmacol. 1979, 3, 161-166.
4. Evans, W.E.; Crom, W.R.; Abromowitch, M.; Dodge, R.; Look, A.T.; Bowman, W.P.; George, S.L.; Pui, C.H. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. New Engl. J. Med. 1986, 314, 471-477.
5. Evans, W.E.; Relling, M.V.; Rodman, J.H.; Crom, W.R.; Boyett, J.M.; Pui, C.H. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. New Engl. J. Med. 1998, 338, 499-505.
6. Pui, C.H.; Evans, W.E. Treatment of acute lymphoblastic leukemia. New Engl. J. Med. 2006, 354, 166-178.
7. Gamelin, E.; Delva, R.; Jacob, J.; Merrouche, Y.; Raoul, J.L.; Pezet, D.; Dorval, E.; Piot, G.; Morel, A.; Boisdron-Celle, M. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26, 2099-2105.
8. Saif, M.W.; Choma, A.; Salamone, S.J.; Chu, E. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J. Nat. Cancer Inst. 2009, 101, 1-10.
9. de Jonge, M.E.; Huitema, A.D.R.; Schellens, J.H.M.; Rodenhuis, S.; Beijnen, J.H. Individualised cancer chemotherapy: Strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. Clin. Pharmacokinet. 2005, 44, 147-173.
10. Galpin, A.J.; Evans, W.E. Therapeutic drug monitoring in cancer management. Clin. Chem. 1993, 39, 2419-2430.
11. Krynetski, E.Y.; Evans, W.E. Pharmacogenetics of cancer therapy: getting personal. Am. J. Hum. Genet. 1998, 63, 11-16.
12. Rousseau, A.; Marquet, P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam. Clin. Pharmacol. 2002, 16, 253-262.
13. Holzer, A.K.; Katano, K.; Klomp, L.W.J.; Howell, S.B. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin. Cancer Res. 2004, 10, 6744-6749.
14. Schiffer, R.; Neis, M.; Höller, D.; Rodríguez, F.; Geier, A.; Gartung, C.; Lammert, F.; Dreuw, A.; Zwadlo-Klarwasser, G.; Merk, H.; Jugert, F.; Baron, J.M. Active influx transport is mediated by members of the organic anion transporting polypeptide family in human epidermal keratinocytes. J. Invest. Dermatol. 2003, 120, 285-291.
15. Suzuki, H.; Sugiyama, Y. Transport of drugs across the hepatic sinusoidal membrane: sinusoidal drug influx and efflux in the liver. Semin. Liver Dis. 2000, 20, 251-263.
16. Kato, Y.; Miyazaki, T.; Kano, T.; Sugiura, T.; Kubo, Y.; Tsuji, A. Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J. Pharma. Sci. 2009, 98, 2529-2539.
17. Tomlinson, E. Theory and practice of site-specific drug delivery. Adv. Drug Deliver. Rev. 1987, 1, 87-198.
18. Schnitzer, J.E. Update on the cellular and molecular basis of capillary permeability. Trends Cardiovasc. Med. 1993, 3, 124-130.
19. Schnitzer, J.E. Vascular targeting as a strategy for cancer therapy. N. Engl. J. Med. 1998, 339, 472-474.
20. Denekamp, J. Vasculature as a target for tumour therapy. Prog. Appl. Microcirc. 1984, 4, 28-38.
21. Burrows, F.J.; Thorpe, P.E. Vascular targeting - a new approach to the therapy of solid tumors. Pharmacol. Ther. 1994, 64, 155-174.
22. Dykes, P.W.; Bradwell, A.R.; Chapman, C.E.; Vaughan, A.T.M. Radioimmunotherapy of cancer, clinical studies and limiting factors. Cancer Treat. Rev. 1987, 14, 87-106.
23. Jain, R.K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 1990, 50, 814s-819s.
24. Sands, H.; Jones, P.L. Physiology of monoclonal antibody accretion by tumors. Cancer Treat. Res. 1990, 51, 97-122.
25. Arap, W.; Pasqualini, R.; Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998, 279, 377-380.
26. Christofidou-Solomidou, M.; Pietra, G.G.; Solomides, C.C.; Arguiris, E.; Harshaw, D.; Fitzgerald, G.A.; Albelda, S.M.; Muzykantov, V.R. Immunotargeting of glucose oxidase to endothelium in vivo causes oxidative vascular injury in the lungs. Am. J. Physiol. Lung Cell Mol. Physiol. 2000, 278, L794-L805.
27. Holton, O.D.; Black, C.D.; Parker, R.J.; Covell, D.G.; Barbet, J.; Sieber, S.M.; Talley, M.J.; Weinstein, J.N. Biodistribution of monoclonal IgG1, F(ab ́)2, and Fab ́ in mice after intravenous injection. Comparison between anti-B cell (anti-Lyb8.2) and irrelevant (MOPC-21) antibodies. J. Immunol. 1987, 139, 3041-3049.
28. Hughes, B.J.; Kennel, S.; Lee, R.; Huang, L. Monoclonal antibody targeting of liposomes to mouse lung in vivo. Cancer Res. 1989, 49, 6214-6220.
29. Pasqualini, R.; Ruoslahti, E. Organ targeting in vivo using phage display peptide libraries. Nature 1996, 380, 364-366.
30. Pimm, M.V.; Baldwin, R.W. Quantitative evaluation of the localization of a monoclonal antibody (791T/36) in human osteogenic sarcoma xenografts. Eur. J. Cancer Clin. Oncol. 1984, 20, 515-524.
31. Weinstein, J.N.; van Osdol, W. The macroscopic and microscopic pharmacology of monoclonal antibodies. Int. J. Immunopharmacol. 1992, 14, 457-463.
32. Ferrari, M. Cancer nanotechnology, opportunities and challenges. Nat. Rev. Cancer 2005, 5, 161-171.
33. Dvorak, H.F.; Nagy, J.A.; Dvorak, A.M. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells 1991, 3, 77-85.
34. Baker, M. Upping the ante on antibodies. Nat. Biotechnol. 2005, 23, 1065-1072.
35. Glennie, M.J.; Johnson, P.W.M. Clinical trials of antibody therapy. Trends Immunol. 2000, 21, 403-410.
36. Fair, W.R.; Israeli, R.S.; Heston, W.D.W. Prostate-specific membrane antigen. Prostate 1997, 32, 140-148.
37. Gao, X.; Porter, A.T.; Grignon, D.J.; Pontes, J.E.; Honn, K.V. Diagnostic and prognostic markers for human prostate cancer. Prostate 1997, 31, 264-281.
38. Murphy, G.P.; Barren, R.J.; Erickson, S.J.; Bowes, V.A.; Wolfert, R.L.; Bartsch, G.; Klocker, H.; Pointner, J.; Reissigl, A.; McLeod, D.G.; Douglas, T.; Morgan, T.; Kenny, G.M.; Ragde, H.; Boynton, A.L.; Holmes, E.H. Evaluation and comparison of two new prostate carcinoma markers: Free-prostate specific antigen and prostate specific membrane antigen. Cancer 1998, 78, 809-818.
39. Jain, R.K. Understanding barriers to drug delivery: high resolution in vivo imaging is key. Clin. Cancer Res. 1999, 5, 1605-1606.
40. Torchilin, V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. Nanotechnol. Drug Deliv. 2007, 9, E128-E147.
41. Dimotakis, P.E. The mixing transition in turbulent flows. J. Fluid Mechan. 2000, 409, 69-98.
42. Presley, J.F.; Mayor, S.; McGraw, T.E.; Dunn, K.W.; Maxfield, F.R. Bafilomycin A1 treatment retards transferrin receptor recycling more than bulk membrane recycling. J. Biol. Chem. 1997, 272, 13929-13936.
43. Paulos, C.M.; Reddy, J.A.; Leamon, C.P.; Turk, M.J.; Low, P.S. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery. Mol. Pharmacol. 2004, 66, 1406-1414.
44. Benacerraf, B.; Sebestyen, M.; Cooper, N.S. The clearance of antigen-antibody complexes from the blood by the reticulo-endothelial system. J. Immunol. 1959, 82, 131-137.
45. Jain, R.K. The next frontier of molecular medicine: delivery of therapeutics. Nat. Med. 1998, 4, 655-657.
46. Thrush, G.R.; Lark, L.R.; Clinchy, B.C.; Vitetta, E.S. Immunotoxins: an update. Annu. Rev. Immunol. 1996, 14, 49-71.
47. Harvey, S.J.; Miner, J.H. Revisiting the glomerular charge barrier in the molecular era. Curr. Opin. Nephrol. Hypertension 2008, 17, 393-398.
48. Kossmann, C.E.; Palade, G.E. Blood capillaries of the heart and other organs. Circulation 1961, 24, 368-384.
49. Lum, H.; Malik, A.B. Regulation of vascular endothelial barrier function. Am. J. Physiol. Lung Cell Mol. Physiol. 1994, 267, L223-L241.
50. Zhou, H.; Ohno, N.; Terada, N.; Saitoh, S.; Fujii, Y.; Ohno, S. Involvement of follicular basement membrane and vascular endothelium in blood-follicle barrier formation of mice revealed by 'in vivo cryotechnique'. Reproduction 2007, 134, 307-317.
51. Wieser, E.; Strohmeyer, D.; Rogatsch, H.; Horninger, W.; Bartsch, G.; Debbage, P; Access of tumor-derived macromolecules and cells to the blood: an electron microscopical study of structural barriers in microvessel clusters in highly malignant primary prostate carcinomas. Prostate 2004, 62, 123-132.
52. Bucior, I.; Scheuring, S.; Engel, A.; Burger, M.M. Carbohydrate-carbohydrate interaction provides adhesion force and specificity for cellular recognition. J. Cell Biol. 2004, 165, 529-537.
53. Santacroce, M.; Orsini, F.; Mari, S.A.; Marinone, M.; Lenardi, C.; Bettè, S.; Sacchi, V.F.; Poletti, G. Atomic force microscopy imaging of Xenopus laevis oocyte plasma membrane purified by ultracentrifugation. Microsc. Res. Tech. 2008, 71, 397-402.
54. Tate, R.L.; Holmes, J.M.; Kohn, L. Characteristics of a solubilized thyrotropin receptor from bovine thyroid plasma membranes. J. Biol. Chem. 1975, 250, 6527-6533.
55. Ando, T.; Davies, T.F. Monoclonal antibodies to the thyrotropin receptor. Clin. Devel. Immunol. 2005, 12, 137-143.
56. Camarillo, I.G.; Thordarson, G.; Moffat, J.G.; van Horn, K.M.; Binart, N.; Kelly, P.A.; Talamantes, F. Prolactin receptor expression in the epithelia and stroma of the rat mammary gland. J. Endocrinol. 2001, 171, 85-95.
57. Barker, S.; Laird, S.M.; Ho, M.M.; Vinson, G.P.; Hinson, J.P. Characterization of a rat adrenocortical inner zone-specific antigen and identification of its putative precursor. J. Mol. Endocrinol. 1992, 9, 95-102.
58. Molineux, I.J. No syringes please, ejection of phage T7 DNA from the virion is enzyme driven. Mol. Microbiol. 2001, 40, 1-8.
59. Förster, C. Tight junctions and the modulation of barrier function in disease. Histochem. Cell Biol. 2008, 130, 55-70.
60. Minn, A.; Ghersi-Egea, J.F.; Perrin, R.; Leininger, B.; Siest, G. Drug metabolizing enzymes in the brain and cerebral microvessels. Brain Res. Rev. 1991, 16, 65-82.
61. Brownlees, J.; Williams, C.H. Peptidases, peptides and the mammalian blood-brain barrier. J. Neurochem. 1993, 60, 793-803.
62. Abbott, N.J.; Romero, I.A. Transporting therapeutics across the blood-brain barrier. Mol. Med. Today 1996, 2, 106-113.
63. Beigneux, A.P.; Davies, B.S.J.; Gin, P.; Weinstein, M.M.; Farber, E.; Qiao, X.; Peale, F.; Bunting, S.; Walzem, R.L.; Wong, J.S.; Blaner, W.S.; Ding, Z.M.; Melford, K.; Wongsiriroj, N.; Shu, X.; de Sauvage, F.; Ryan, R.O.; Fong, L.G.; Bensadoun, A.; Young, S.G. Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab. 2007, 5, 279-291.
64. van Haaren, P.M.A.; van Bavel, E.; Vink, H.; Spaan, J.A.E. Charge modification of the endothelial surface layer modulates the permeability barrier of isolated rat mesenteric small arteries. Am. J. Physiol. Heart Circ. Physiol. 2005, 289, H2503-H2507.
65. Cullere, X.; Shaw, S.K.; Andersson, L.; Hirahashi, J.; Luscinskas, F.W.; Mayadas, T.N. Regulation of vascular endothelial barrier function by Epac, a cAMP-activated exchange factor for Rap GTPase. Blood 2005, 105, 1950-1955.
66. Brunskill, N.J.; Stuart, J.; Tobin, A.B.; Walls, J.; Nahorski, S. Receptor-mediated endocytosis of albumin by kidney proximal tubule cells is regulated by phosphatidylinositide 3-kinase. J. Clin. Invest. 1998, 101, 2140-2150.
67. Joó, F. The role of second messenger molecules in the regulation of permeability in the cerebral endothelial cells. Adv. Exp. Med. Biol. 1993, 331, 155-164.
68. Keys, J.L.; King, G.J. Morphology of pig uterine subepithelial capillaries after topical and systemic oestrogen treatment. J. Reprod. Fertil. 1995, 105, 287-294.
69. Schnitzer, J.E.; McIntosh, D.P.; Dvorak, A.M.; Liu, J.; Oh, P. Separation of caveolae from associated microdomains of GPI-anchored proteins. Science 1995, 269, 1435-1439.
70. Zlokovic, B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57, 178-201.
71. Bannerman, D.D.; Paape, M.J.; Hare, W.R.; Sohn, E.J. Increased levels of LPS-binding protein in bovine blood and milk following bacterial lipopolysaccharide challenge. J. Dairy Sci. 2003, 86, 3128-3137.
72. Disson, O.; Grayo, S.; Huillet, E.; Nikitas, G.; Langa-Vives, F.; Dussurget, O.; Ragon, M.; Le Monnier, A.; Babinet, C.; Cossart, P.; Lecuit, M. Conjugated action of two species-specific invasion proteins for fetoplacental listeriosis. Nature 2008, 455, 1114-1118.
73. Le Monnier, A.; Autret, N.; Join-Lambert, O.F.; Jaubert, F.; Charbit, A.; Berche, P.; Kalyal, S. ActA is required for crossing of the fetoplacental barrier by Listeria monocytogenes. Infect. Immun. 2007, 75, 950-957.
74. Chiovato, L.; Latrofa, F.; Braverman, L.E.; Pacini, F.; Capezzone, M.; Masserini, L.; Grasso, L.; Pinchera, A. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann. Intern. Med. 2003, 139, 346-351.
75. Fulmer, B.R.; Turner, T.T. A blood-prostate barrier restricts cell and molecular movement across the rat ventral prostate epithelium. J. Urol. 2000, 163, 1591-1594.
76. Schadewinkel-Scherkl, A.M.; Rasmussen, F.; Merck, C.C.; Nielsen, P.; Frey, H.H. Active transport of benzyl-penicillin across the blood-milk barrier. Pharmacol. Toxicol. 2009, 73, 14-19.
77. Banerjee, D.K.; Ornberg, R.L.; Youdim, M.B.H.; Heldman, E.; Pollard, H.B. Endothelial cells from bovine adrenal medulla develop capillary-like growth patterns in culture. Proc. Natl. Acad. Sci. USA 1985, 82, 4702-4706.
78. Bennett, H.S.; Luft, J.H.; Hampton, J.C. Morphological classifications of vertebrate blood capillaries. Am. J. Physiol. 1959, 196, 381-390.
79. Friend, D.S.; Gilula, N.B. Variations in tight and gap junctions in mammalian tissues. J. Cell Biol. 1972, 53, 758-776
80. Lewandowsky, M. Zur Lehre der Zerebrospinalflüssigkiet. Z. Klin. Med. 1890, 40, 480-494.
81. Biedl, A.; Kraus, R. Über eine bisher unbekannte toxische Wirkung der Gallensäure auf das Zentralnervensystem. Zentralbl. Inn. Med. 1898, 19, 1185-1200.
82. Ehrlich, P. Über die Beziehung chemischer Constitution, Vertheilung, und pharmakologischer Wirkung; Gesammelte Arbeiten zur Immunitätsforschung: Berlin, Germany, 1904.
83. Goldmann, E.E. Vitalfärbung am Zentralnervensystem. Abh. Preuss. Wissensch. Phys. Math. 1913, 1,1-60.
84. Reese, T.S.; Karnovsky, M.J. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J. Cell Biol. 1967, 34, 207-217.
85. Brightman, M.W.; Reese, T.S. Junctions between intimately apposed cell membranes in the vertebrate brain. J. Cell Biol. 1969, 40, 648-677.
86. Simionescu, M.; Popov, D.; Sima, A. Endothelial transcytosis in health and disease. Cell Tissue Res. 2009, 335, 27-40.
87. Dempsey, E.W.; Wislocki, G.B. An electron microscopic study of the blood-brain barrier in the rat, employing silver nitrate as a vital stain. J. Biophys. Biochem. Cytol. 1955, 1, 245-256.
88. Dermietzel, R.; Krause, D. Molecular anatomy of the blood-brain barrier as defined by immunocytochemistry. Int. Rev. Cytol. 1991, 127, 57-109.
89. Revest, P.A.; Jones, H.C.; Abbott, N.J. The transendothelial DC potential of rat blood-brain barrier vessels in situ. Adv. Exp. Med. Biol. 1993, 331, 71-74.
90. Pardridge, W.M.; Boado, R.J.; Farrell, C.R. Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. Studies with quantitative western blotting and in situ hybridization. J. Biol. Chem. 1990, 265, 18035-18040.
91. Duport, S.; Robert, E.; Muller, D.; Grau, G.; Parisi, L.; Stoppini, L. An in vitro blood-brain barrier model: cocultures between endothelial cells and organotypic brain slice cultures. Proc. Natl. Acad. Sci. USA 1998, 95, 1840-1845.
92. Green, E. Blood-brain barrier: Size matters at the blood-brain barrier. Nat. Rev. Neurosci. 2003, 4, 525.
93. Abbott, N.J.; Rönnbäck, L.; Hansson, E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 2006, 7, 41-53.
94. Bradbury, M.W.B. The blood-brain barrier. Exp. Physiol. 1993, 78, 453-472.
95. Bonetta, L. Endothelial tight junctions form the blood-brain barrier. J. Cell Biol. 2005, 169, 378-379.
96. Engelhardt, B. Development of the blood-brain barrier. Cell Tissue Res. 2003, 314, 119-129.
97. Cardoso, F.L.; Brites, D.; Brito, M.A. Looking at the blood-brain barrier: Molecular anatomy and possible investigation approaches. Brain Res. Rev. 2010, doi:10.1016/j.brainresrev.2010.05.003.
98. Persidsky, Y.; Ramirez, S.H.; Haorah, J.; Kanmogne, G.D. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J. Neuroimmune Pharmacol. 2006, 1, 223-236.
99. Rubin, L.L.; Staddon, J.M. The cell biology of the blood-brain barrier. Annu. Rev. Neurosci. 1999, 22, 11-28.
100. Ueno, M. Molecular anatomy of the brain endothelial barrier: an overview of the distributional features. Curr. Med. Chem. 2007, 14, 1199-1206.
101. Holash, J.A.; Harik, S.I.; Perry, G.; Stewart, P.A. Barrier properties of testis microvessels. Proc. Natl. Acad. Sci. USA 1993, 90, 11069-11073.
102. Wong, C.H.; Cheng, C.Y. The blood-testis barrier: its biology, regulation, and physiological role in spermatogenesis. Curr. Top. Dev. Biol. 2005, 71, 263-296.
103. Debbage, P.L.; Sölder, E.; Seidl, S.; Hutzler, P.; Hugl, B.; Öfner, D.; Kreczy, A. Intravital lectin perfusion analysis of vascular permeability in human micro- and macro- blood vessels. Histochem. Cell Biol. 2001, 116, 349-359.
104. Enders, A.C.; Blankenship, T.N. Comparative placental structure. Adv. Drug Deliv. Rev. 1999, 38, 3-15.
105. Soelder, E.; Hutzler, P.; Debbage, P. Permeabilitäten im Plazentaren Gefässbaum am Termin. 23. Jahrestagung der Österreichischen Gesellschaft für Reproduktionsmedizin und Endokrinologie, 20-22 September 2007, Innsbruck, Austria.
106. Sölder, E.; Kremser, C.; Rohr, I.; Hutzler, P.; Debbage, P. Molecular mapping deep within a living human organ: analysis of microvessel function on the timescale of seconds and with submicrometre spatial resolution. Histochem. Cell Biol. 2009, 131, 537-551.
107. Soelder, E.; Rohr, I.; Hutzler, P.; Debbage, P. Imaging of placental transport mechanisms: a review. Eur. J. Obstet. Gynecol. Reprod. Biol. 2009, 144 (Suppl. 1), 114-120.
108. Vähäkangas, K.; Myllynen, P. Drug transporters in the human blood-placental barrier. Brit. J. Pharm. 2009, 158, 665-678.
109. Tzelepi, V.N.; Tsamandas, A.C.; Vlotinou, H.D.; Vagianos, C.E.; Scopa, C.D. Tight junctions in thyroid carcinogenesis: diverse expression of claudin-1, claudin-4, claudin-7 and occludin in thyroid neoplasms. Mod. Pathol. 2008, 21, 22-30.
110. Shennan, D.B.; Peaker, M. Transport of milk constituents by the mammary gland. Physiol. Rev. 2000, 80, 925-951.
111. McManaman, J.L.; Neville, M.C. Mammary physiology and milk secretion. Adv. Drug Delivery Rev. 2003, 55, 629-641.
112. Nguyen, D.D.; Neville, M.C. Tight junction regulation in the mammary gland. J. Mammary Gland Biol. Neopl. 1998, 3, 233-246.
113. Monks, J.; Neville, M.C. Albumin transcytosis across the epithelium of the lactating mouse mammary gland. J. Physiol. 2004, 560, 267-280.
114. Linzell, J.L.; Peaker, M. Changes in colostrum composition and in the permeability of the mammary epithelium at about the time of parturition in the goat. J. Physiol. 1974, 243, 129-151.
115. Berga, S.E. Electrical potentials and cell-to-cell dye movement in mouse mammary gland during lactation. Am. J. Physiol. Cell Physiol. 1984, 247, C20-C25.
116. Nguyen, D.D.; Parlow, A.F.; Neville, M.C. Hormonal regulation of tight junction closure in the mouse mammary epithelium during the transition from pregnancy to lactation. J. Endocrinol. 2001, 170, 347-356.
117. Halsey, J.F.; Mitchell, C.; Meyer, R.; Cebra, J.J. Metabolism of immunoglobulin A in lactating mice: origins of immunoglobulin A in milk. European J. Immunol. 1982, 12, 107-112.
118. Geursen, A.; Grigor, M.R. Serum albumin secretion in rat milk. J. Physiol. 1987, 391, 419-427
119. Swaisgood, H.E. Protein and amino acid composition of bovine milk. In Handbook of Milk Composition; Jensen, R.G., Eds.; Academic Press: San Diego, Washington DC, USA, 1995. pp. 464-467.
120. Lonnerdal, B.; Atkinson, S. Nitrogenous components of milk: A. Human milk proteins. In Handbook of Milk Composition; Jensen, R.G., Ed.; Academic Press: Washington DC, USA, 1995; pp. 352-368.
121. Jain, N.C.; Schalm, O.W.; Carroll, E.J.; Lasmanis, J. Experimental mastitis in leukopenic cows: immunologically induced neutropenia and response to intra-mammary inoculation of Aerobacter aerogenes. Am. J. Vet. Res. 1968, 37, 2089-2097.
122. Carlos, T.M.; Harlan, J.M. Membrane proteins involved in phagocyte adherence to endothelium. Immunol. Rev. 1990, 114, 5-28.
123. Guidry, A.J.; O'Brien, C.N.; Douglass, L.W. A bovine mammary endothelial/epithelial cell culture model of the blood/milk barrier. Can. J. Vet. Res. 1998, 62, 117-121.
124. Landis, E.M.; Pappenheimer, J.R. Exchange of substances through the capillary walls. Handb. Physiol. 1963, 2, 961-1034.
125. Palade, G.E. Blood capillaries of the heart and other organs. Circulation 1961, 24, 368-384.
126. Jennings, M.A.; Marchesi, V.T.; Florey, H. The transport of particles across the walls of small blood vessels. Proc. R. Soc. Lond. B. Biol. Sci. 1962, 156, 14-19.
127. Weihe, E.; Kalmbach, P. Ultrastructure of capillaries in the conduction system of the heart in various mammals. Cell Tissue Res. 1978, 192, 77-87.
128. Anversa, P.; Giacomelli, F.; Wiener, J. Intercellular junctions of rat endocardium. Anat. Rec. 1975, 183, 477-483.
129. Bruns, R.R.; Palade, G.E. Studies on blood capillaries: II. The transport of ferritin molecules across the wall of muscle capillaries. J. Cell Biol. 1968, 37, 277-299.
130. Karnovsky, M.J. Vesicular transport of exogenous peroxidase across capillary endothelium into the T system of muscle. J. Cell Biol. 1965, 27, 49A-50A.
131. Palade, G.E. Fine structure of blood capillaries. J. Appl. Phys. 1953, 24, 1424.
132. Simionescu, N.; Simionescu, M.; Palade, G.E. Permeability of muscle capillaries to exogenous myoglobin. J. Cell Biol. 1973, 57, 2424-2452.
133. Karnovsky, M.J. The ultrastructural basis of capillary permeability studied with peroxidase as a tracer. J. Cell Biol. 1967, 35, 213-236.
134. Williams, M.C.; Wissig, S.L. The permeability of muscle capillaries to horseradish peroxidase. J. Cell Biol. 1975, 66, 531-555.
135. Schlingemann, R.O.; Hofman, P.; Klooster, J.; Blaauwgeers, H.G.T.; Van der Gaag, R.; Vrensen, G.F.J.M. Ciliary muscle capillaries have blood-tissue barrier characteristics. Exp. Eye Res. 1998, 66, 747-754.
136. Pietra, G.G.; Szidon, J.P.; Leventhal, M.M.; Fishman, A.P. Hemoglobin as a tracer in hemodynamic pulmonary edema. Science 1969, 166, 1643-1646.
137. Schneeberger, E.E.; Karnovsky, M.J. The influence of intravascular fluid volume on the permeability of newborn and adult mouse lungs to ultrastructural protein tracers. J. Cell Biol. 1971, 49, 319-334.
138. Schneeberger, E.E.; Karnovsky, M.J. The ultrastructural basis of alveolar-capillary membrane permeability to peroxidase used as a tracer. J. Cell Biol. 1975, 37, 781-793.
139. Schneeberger, E.E.; Karnovsky, M.J. Substructure of intercellular junctions in freeze-fractured alveolar-capillary membranes of mouse lung. Circ. Res. 1976, 38, 404-411.
140. Kim, K.-J.; Malik, A.B. Protein transport across the lung epithelial barrier. Am. J. Physiol. Lung Cell Mol. Physiol. 2003, 284, L247-L259.
141. Chapman, A.L.; Bopp, W.J. Electron microscopy of vascular barrier in thymus, tonsil, and lymph node of beagle pups. Am. J. Vet. Res. 1970, 31, 1255-1268.
142. Abe, K.; Ito, T. Vascular permeability in the thymus of the mouse. Arch. Histol. Jpn. 1974, 36, 251-264.
143. Mikata, A.; Niki, R. Permeability of postcapillary venules of the lymph node. An electron microscopic study. Exp. Mol. Pathol. 1971, 14, 289-305.
144. Raviola, E.; Karnovsky, M.J. Evidence for a blood-thymus barrier using electron-opaque tracers. J. Exp. Medicine 1972, 136, 466-498.
145. Kimm, M.H.; Hardin, J.A.; Gall, D.G. Transport of albumin into the intestinal lumen of the rat. Can. J. Physiol. Pharmacol. 1997, 75, 193-198.
146. Simionescu, M.; Simionescu, N.; Palade, G.E. Permeability of intestinal capillaries. Pathway followed by dextrans and glycogen. J. Cell Biol. 1972, 53, 365-392.
147. Sztul, E.S.; Howell, K.E.; Palade, G.E. Intracellular transport of secretory component and albumin in rat hepatocytes. J. Cell Biol. 1983, 97, 1582-1591.
148. Maltby, B.; Lemon, G.J.; Bassingthwaighte, J.B.; Kelly, P.J. Exchange of potassium and strontium in adult bone. Am. J. Physiol. Heart Circ. Physiol. 1982, 242, H705-H712.
149. Sörensson, J.; Matejka, G.L.; Ohlson, M.; Haraldsson, B. Human endothelial cells produce orosomucoid, an important component of the capillary barrier. Am. J. Physiol. Heart Circ. Physiol. 1999, 276, H530-H534.
150. Dvorak, H.F. How tumors make bad blood vessels and stroma. Am. J. Pathol. 2003, 162, 1747-1757.
151. Shlosberg, D.; Benifla, M.; Kaufer, D.; Friedman, A. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat. Rev. Neurol. 2010, 6, 393-403.
152. Petrovski, K.R.; Stefanov, E. Milk composition changes during mastitis. www.milkproduction.com.
153. Antonetti, D.A.; Barber, A.J.; Khin, S.; Lieth, E.; Tarbell, J.M.; Gardner, T.W. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content. Vascular endothelial growth factor decreases occludin in retinal endothelial cells. Diabetes 1998, 47, 1953-1959.
154. Greenwood, J. Mechanisms of blood-brain barrier breakdown. Neuroradiology 2004, 33, 95-100.
155. Schneider, S.W.; Ludwig, T.; Tatenhorst, L.; Braune, S.; Oberleithner, H.; Senner, V.; Paulus, W. Glioblastoma cells release factors that disrupt blood-brain barrier feature. Acta Neuropathol. 2004, 107, 272-276.
156. Roberts, H.C.; Roberts, T.P.L.; Brasch, R.C.; Dillon, W.P. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. Am. J. Neuroradiol. 2000, 21, 891-899.
157. Cohen, F.M.; Kuwatsuru, R.; Shames, D.M.; Neuder, M.; Mann, J.S.; Vexler, V.; Rosenau, W.; Brasch, R.C. Contrast-enhanced magnetic resonance imaging estimation of altered capillary permeability in experimental mammary carcinomas after X-irradiation. Investig. Radiol. 1994, 29, 970-977.
158. Baillie, C.T.; Winslet, M.C.; Bradley, N.J. Tumour vasculature - a potential therapeutic target. Brit. J. Cancer 1995, 72, 257-267.
159. Denekamp, J.; Hobson, B. Endothelial cell proliferation in experimental tumours. Brit. J. Cancer 1982, 46, 711-720.
160. Warren, B.A. The vascular morphology of tumors. In Tumor Blood Circulation: Angiogenesis, Vascular Morphology and Blood Flow of Experimental and Human Tumors; Peterson, H., Ed.; CRC Press: Boca Raton, FL, 1979; pp. 1-47.
161. Mattsson, J.; Appelgren, L.; Hamberger, B.; Peterson, H. Tumor vessel innervation and influence of vasoactive drugs on tumor blood flow. In Tumor Blood Circulation: Angiogenesis, Vascular Morphology and Blood Flow of Experimental and Human Tumors; Peterson, H., Ed.; CRC Press: Boca Raton, FL, 1979; pp. 129-135.
162. Dvorak, H.F.; Nagy, J.A.; Dvorak, J.T.; Dvorak, A.M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 1988, 133, 95-109.
163. Furman-Haran, E.; Margalit, R.; Grobgeld, D.; Degani, H. Dynamic contrast-enhanced magnetic resonance imaging reveals stress-induced angiogenesis in MCF7 human breast tumors. Proc. Natl. Acad. Sci. USA 1996, 93, 6247-6251.
164. van Dijke, C.F.; Brasch, R.C.; Roberts, T.P.; Weidner, N.; Mathur, A.; Shames, D.M.; Mann, J.S.; Demsar, F.; Lang, P.; Schwickert, H.C. Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density. Radiology 1996, 198, 813-818.
165. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65, 271-284.
166. Greish, K. Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines. J. Drug Targeting 2007, 15, 457-464.
167. Iyer, A.K.; Greish, K.; Fang, J.; Maeda, H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 2006, 11, 812-818.
168. Tanaka, T.; Shiramoto, S.; Miyashita, M.; Fujishima, Y.; Kaneo, Y. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int. J. Pharm. 2004, 277, 39-61.
169. Lamprecht, A. IBD: Selective nanoparticle adhesion can enhance colitis therapy. Nat. Rev. Gastroenterol. Hepatol. 2010, 7, 311-312.
170. Wang, D.; Miller, S.C.; Liu, X-M.; Anderson, B.; Wang, X.S.; Goldring, S.R. Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis. Arthr. Res. Therap. 2007, 9, R2.
171. Tarner, I.H.; Müller-Ladner, U. Drug delivery systems for the treatment of rheumatoid arthritis. Expert Opin. Drug Deliv. 2008, 5, 1027-1037.
172. Lukyanov, A.N.; Hartner, W.C.; Torchilin, V.P. Increased accumulation of PEG-PE micelles in the area of experimental myocardial infarction in rabbits. J. Control. Release 2004, 94, 187-193.
173. Schiffelers, R.M.; Banciu, M.; Metselaar, J.M.; Storm, G. Therapeutic application of longcirculating liposomal glucocorticoids in auto-immune diseases and cancer. J. Liposome Res. 2006, 16, 185-194.
174. Mulder, W.J.M.; Strijkers, G.J.; van Tilborg, G.A.F.; Griffioen, A.W.; Nicolay, K. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed. 2006, 19, 142-164.
175. Desai, B.S.; Monahan, A.J.; Carvey, P.M.; Hendey, B. Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplant. 2007, 16, 285-299.
176. Kalaria, R.N. The blood-brain barrier and cerebrovascular pathology in Alzheimer's Disease. Ann. N. York Acad. Sci. 2006, 893, 113-125.
177. Lien, W.M.; Ackerman, N.B. The blood supply of experimental liver metastases. II. A microcirculatory study of normal and tumor vessels of the liver with the use of perfused silicone rubber. Surgery 1970, 68, 334-340.
178. Molema, G.; de Leij, L.F.; Meijer, D.K. Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy. Pharm. Res. 1997, 14, 2-10.
179. Béduneau, A.; Saulnier, P.; Benoit, J-P. Active targeting of brain tumors using nanocarriers. Biomaterials 2007, 28, 4947-4967.
180. Debbage, P.; Jaschke, W. Molecular imaging with nanoparticles: giant roles for dwarf actors. Histochem. Cell Biol. 2008, 130, 845-875.
181. Pardridge, W.M. CNS drug design based on principles of blood-brain barrier transport. J. Neurochem. 1998, 70, 1781-1792.
182. Vaughan, A.T.M.; Anderson, P.; Dykes, P.W.; Chapman, C.E.; Bradwell, A.R. Limitations to the killing of tumours using radiolabelled antibodies. Brit. J. Radiol. 1987, 60, 567-572.
183. Mathijssen, R.H.J.; de Jong, F.A.; Loos, W.J.; van der Bol, J.M.; Verweij, J.; Sparreboom, A. Flat-fixed dosing versus body surface area-based dosing of anticancer drugs in adults: Does it make a difference? Oncologist 2007, 12, 913-923.
184. Walko, C.M.; McCloud, H.L. Will we ever be ready for blood level-guided therapy? J. Clin. Oncol. 2008, 26, 2078-2079.
185. Debbage, P. Targeted drugs and nanomedicine: present and future. Curr. Pharm. Design 2009, 15, 153-172.
186. McIntosh, D.P.; Tan, X-Y.; Oh, P.; Schnitzer, J.E. Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc. Nat. Acad. Sci. USA 2002, 99, 1996-2001.
187. Siegal, T.; Rubinstein, R.; Bokstein, F.; Schwartz, A.; Lossos, A.; Shalom, E.; Chisin, R.; Gomori, J.M. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans. J. Neurosurg. 2000, 92, 599-605.
188. Greenwood, J.; Mason, J.C. Statins and the vascular endothelial inflammatory response. Trends Immunol. 2007, 28, 88-98.
189. Kimura, H.; Weisz, A.; Kurashima, Y.; Hashimoto, K.; Ogura, T.; D'Acquisto, F.; Addeo, R.; Makuuchi, M.; Esumi, H. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 2000, 95, 189-197.
190. Kreuter, J.; Alyautdin, R.N.; Kharkevich, D.A.; Ivanov, A.A. Passage of peptides through the bloodbrain barrier with colloidal polymer particles (nanoparticles). Brain Res. 1995, 674, 171-174.
191. Sun, W.; Xie, C.; Wang, H.; Hu, Y. Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials 2004, 25, 3065-3071.
192. Flacke, S.; Fischer, S.; Scott, M.J.; Fuhrhop, R.J.; Allen, J.S.; McLean, M.; Winter, P.; Sicard, G.A.; Gaffney, P.J.; Wickline, S.A.; Lanza, G.M. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 2001, 104, 1280-1285.
193. Winter, P.M.; Cai, K.; Chen, J.; Adair, C.R.; Kiefer, G.E.; Athey, P.S.; Gaffney, P.J.; Buff, C.E.; Robertson, J.D.; Caruthers, S.D.; Wickline, S.A.; Lanza, G.M. Targeted PARACEST nanoparticle contrast agent for the detection of fibrin. Magn. Reson. Med. 2006, 56, 1384-1388.
194. Miele, E.; Spinelli, G.P.; Miele, E.; Tomao, F.; Tomao, S. Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. Int. J. Nanomed. 2009, 4, 99-105.
195. Malam, Y.; Loizidou, M.; Seifalian, A.M. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 1999, 30, 592-599.
196. Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Nanomedicine: current status and future prospects. FASEB J. 2005, 19, 311-330.
197. Sinha, R.; Kim, G.J.; Nie, S.; Shin, D.M. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther. 2006, 5, 1909-1917.
198. Smith, T.D.; Bhatnagar, K.P.; Tuladhar, P.; Burrows, A.M. Distribution of olfactory epithelium in the primate nasal cavity: Are "microsmia" and "macrosmia" valid morphological concepts? Anatom. Record 2004, 281A, 1173-1181.
199. Nedelec, S.; Dubacq, C.; Trembleau, A. Morphological and molecular features of the mammalian olfactory sensory neuron axons: What makes these axons so special? J. Neurocytol. 2005, 34, 49-64.
200. Dahan, M.; Lévi, S.; Luccardini, C.; Rostaing, P.; Riveau, B.; Triller, A. Diffusion dynamics of glycine receptors revealed by single-quantum dot tracking. Science 2003, 302, 442-445.
201. Zhang, Q.; Li, Y.; Tsien, R.W. The dynamic control of kiss-and-run and vesicular reuse probed with single nanoparticles. Science 2009, 323, 1448-1453.
202. Rajan, S.S.; Vu, T.Q. Quantum dots monitor TrkA receptor dynamics in the interior of neural PC12 cells. Nanoletters 2006, 6, 2049-2059.
203. Wang, Y-C.; Wu, Y-T.; Huang, H-Y.; Lin, H-I.; Lo, L-W.; Tzeng, S-F.; Yang, C-S. Sustained intraspinal delivery of neurotrophic factor encapsulated in biodegradable nanoparticles following contusive spinal cord injury. Biomaterials 2008, 29, 4546-4553.
204. Oberdörster, G.; Elder, A.; Rinderknecht, A. Nanoparticles and the brain: cause for concern? J. Nanosci. Nanotechnol. 2009, 9, 4996-5007.
205. Zhan, J.; Brys, M.; Glodzik, L.; Tsui, W.; Javier, E.; Wegie, J.; Kuchna, I.; Pirraglia, E.; Li, Y.; Mosconi, L.; Saint Louis, L.A.; Switalski, R.; De Santi, S.; Kim, B.C.; Wisniewski, T.; Reisberg, B.; Bobinski, M.; de Leon, M.J. An entorhinal cortex sulcal pattern is associated with Alzheimer's disease. Hum. Brain Mapp. 2009, 3, 874-882.
206. Bergot, A-S.; Durgeau, A.; Levacher, B.; Colombo, B.M.; Cohenand, J.L.; Klatzmann, D. Antigen quality determines the efficiency of antitumor immune responses generated in the absence of regulatory T cells. Cancer Gene Therap. 2010, 17, 645-654.
207. Kaptzan, T.; Skutelsky, E.; Itzhaki, O.; Sinai, J.; Michowitz, M.; Yossipov, Y.; Schiby, G.; Leibovici, J. Age-dependent differences in the efficacy of cancer immunotherapy in C57BL and AKR mouse strains. Exp. Gerontol. 2004, 39, 1035-1048.
208. Trefzer, U.; Weingart, G.; Chen, Y.; Herberth, G.; Adrian, K.; Winter, H.; Audring, H.; Guo, Y.; Sterry, W.; Walden, P. Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int. J. Cancer 2000, 85, 618-626.
209. Chapman, P.T.; Jamar, F.; Keelan, E.T.; Peters, A.M.; Haskard, D.O. Use of a radiolabeled monoclonal antibody against E-selectin for imaging of endothelial activation in rheumatoid arthritis. Arthritis Rheum. 1996, 39, 1371-1375.
210. Jones, S.P.; Trocha, S.D.; Strange, M.B.; Granger, D.N.; Kevil, C.G.; Bullard, D.C.; Lefer, D.J. Leukocyte and endothelial cell adhesion molecules in a chronic murine model of myocardial reperfusion injury. Am. J. Physiol. 2000, 279, H2196-H2201.
211. Schurmann, G.M.; Bishop, A.E.; Facer, P.; Vecchio, M.; Lee, J.C.; Rampton, D.S.; Polak, J.M. Increased expression of cell adhesion molecule P-selectin in active inflammatory bowel disease. Gut 1995, 36, 411-418.
212. Shieh, C-C.; Sadasivan, B.K.; Russell, G.J.; Schön, M.P.; Parker, C.M.; Brenner, M.B. Lymphocyte adhesion to epithelia and endothelia mediated by the lymphocyte endothelialepithelial cell adhesion molecule glycoprotein. J. Immunol. 1999, 163, 1592-1601.
213. Cybulsky, M.I.; Gimbrone, M.A. Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991, 251, 788-791.
214. van der Wal, A.C.; Das, P.K.; Tigges, A.J.; Becker, A.E. Adhesion molecules on the endothelium and mononuclear cells in human atherosclerotic lesions. Am. J. Pathol. 1992, 141, 1427-1433.
215. Clarke, M.S.F.; West, D.C. The identification of proliferation and tumour-induced proteins in human endothelial cells: a possible target for tumour therapy. Electrophoresis 1991, 12, 500-508.
216. Davies, G.; Rmali, K.A.; Watkins, G.; Mansel, R.E.; Mason, M.D.; Jiang, W.G. Elevated levels of tumour endothelial marker-8 in human breast cancer and its clinical significance. Int. J. Oncol. 2006, 29, 1311-1317.
217. Magnussen, A.; Kasman, I.M.; Norberg, S.; Baluk, P.; Murray, R.; McDonald, D.M. Rapid access of antibodies to α5ß1 integrin overexpressed on the luminal surface of tumor blood vessels. Cancer Res. 2005, 65, 2712-2721.
218. Rmali, K.A.; Watkins, G.; Harrison, G.; Parr, C.; Puntis, M.C.A.; Jiang, W.G. Tumour endothelial marker 8 (TEM-8) in human colon cancer and its association with tumour progression. Eur. J. Surg. Oncol. 2004, 30, 948-953.
219. Strickland, L.A.; Jubb, A.M.; Hongo, J-A.; Zhong, F.; Burwick, J.; Fu, L.; Frantz, G.D.; Koeppen, H. Plasmalemmal vesicle-associated protein (PLVAP) is expressed by tumour endothelium and is upregulated by vascular endothelial growth factor-A (VEGF). J. Pathol. 2005, 206, 466-475.
220. Sakhalkar, H.S.; Dalal, M.K.; Salem, A.K.; Ansari, R.; Fu, J.; Kiani, M.F.; Kurjiaka, D.T.; Hanes, J.; Shakesheff, K.M.; Goetz, D.J. Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo. Proc. Natl. Acad. Sci. USA 2003, 100, 15895-15900.
221. Oh, P.; Li, Y.; Yu, J.; Durr, E.; Krasinska, K.M.; Carver, L.A.; Testa, J.E.; Schnitzer, J.E. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissuespecific therapy. Nature 2004, 429, 629-635.
222. Valadon, P.; Garnett, J.D.; Testa, J.E.; Bauerle, M.; Oh, P.; Schnitzer, J.E. Screening phage display libraries for organ-specific vascular immunotargeting in vivo. Proc. Natl. Acad. Sci. USA 2006, 103, 407-412.
223. Brekken, R.A.; Sage, E.H. SPARC, a matricellular protein: at the crossroads of cell-matrix. Matrix Biol. 2000, 19, 569-580.
224. Broadwell, R.D.; Baker-Cairns, B.J.; Friden, P.M.; Oliver, C.; Villegas, J.C. Transcytosis of protein through the mammalian cerebral epithelium and endothelium: III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor. Exp. Neurol. 1996, 142, 47-65.
225. Fishman, J.B.; Rubin, J.B.; Handrahan, J.V.; Connor, J.R.; Fine, R.E. Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J. Neurosci. Res. 1987, 18, 299-304.
226. Jefferies, W.A.; Brandon, M.R.; Hunt, S.V.; Williams, A.F.; Gatter, K.C.; Mason, D.Y. Transferrin receptor on endothelium of brain capillaries. Nature 1984, 312, 162-163.
227. Megias, L.; Guerri, C.; Fornas, E.; Azorin, I.; Bendala, E.; Sancho-Tello, M.; Durán, J.M.; Tomás, M.; Gomez-Lechon, M.J.; Renau-Piqueras, J. Endocytosis and transcytosis in growing astrocytes in primary culture. Possible implications in neural development. Int. J. Dev. Biol. 2000, 44, 209-221.
228. Lu, W.; Zhang, Y.; Tan, Y-Z.; Hu, K-L; Jiang, X-G.; Fu, S-K. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J. Control. Release 2005, 107, 428-448.
229. Zensi, A.; Begley, D.; Pontikis, C.; Legros, C.; Mihoreanu, L.; Wagner, S.; Büchel, C.; von Briesen, H.; Kreuter, J. Albumin nanoparticles targeted with ApoE enter the CNS by transcytosis and are delivered to neurones. J. Control. Release 2009, 137, 78-86.
230. Michaelis, K.; Hoffmann, M.M.; Dreis, S.; Herbert, E.; Alkyautdin, R.N.; Michaelis, M.M.; Kreuter, J.; Langer, K. Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. J. Pharmacol. Exp. Ther. 2006, 317, 1246-1253.
231. Cormode, D.P.; Briley-Saebo, K.C.; Mulder, W.J.; Aguinaldo, J.G.; Barazza, A.; Ma, Y.; Fisher, E.A.; Fayad, Z.A. An ApoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection. Small 2008, 4, 1437-1444.
232. Cormode, D.P.; Chandrasekar, R.; Delshad, A.; Briley-Saebo, K.C.; Calcagno, C.; Barazza, A.; Mulder, W.J.M.; Fisher, E.A.; Fayad, Z.A. Comparison of synthetic high density lipoprotein (HDL) contrast agents for MR imaging of atherosclerosis. Bioconjug. Chem. 2009, 20, 937-943.
233. Frias, J.C.; Ma, Y.; Williams, K.J.; Fayad, Z.A.; Fisher, E.A. Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett. 2006, 6, 2220-2224.
234. Steinman, R.M.; Brodie, S.E.; Cohn, Z.A. Membrane flow during pinocytosis. J. Cell Biol. 1976, 68, 665-687.
235. Oh, P.; Borgström, P.; Witkiewicz, H.; Li, Y.; Borgström, B.J.; Chrastina, A.; Iwata, K.; Zinn, K.R.; Baldwin, R.; Testa, J.E.; Schnitzer, J.E. Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat. Biotechnol. 2007, 25, 327-337.
236. Schnitzer, J.E. Caveolae: from basic trafficking mechanisms to targeting transcytosis for tissuespecific drug and gene delivery in vivo. Adv. Drug Deliv. Rev. 2001, 49, 265-280.
237. Tuma, P.L.; Hubbard, A.L. Transcytosis: crossing cellular barriers. Physiol. Rev. 2003, 83, 871-932
238. Le Roy, C.; Wrana, J.L. Clathrin- and non-clathrin mediated endocytic regulation of cell signaling. Nat. Rev. 2005, 6, 112-126.
239. Miaczynska, M.; Stenmark, H. Mechanisms and functions of endocytosis. J. Cell Biol. 2008,180, 7-11.
240. Qian, Z.M.; Li, H.; Sun, H.; Ho, K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 2002, 54, 561-587.
241. Roth, M.G. Clathrin-mediated endocytosis before fluorescent proteins. Nat. Rev. Mol. Cell Biology 2006, 7, 63-68.
242. Rippe, B.; Rosengren, B-I.; Carlsson, O.; Venturoli, D. Transendothelial transport: the vesicle controversy. J. Vasc. Res. 2002, 39, 375-390.
243. Juurlink, B.H.J.; Devon, R.M. Macromolecular translocation - a possible function of astrocytes. Brain Res. 1990, 533, 73-77.
244. Brightman, M.W. The distribution within the brain of ferritin injected into cerebrospinal fluid compartments. I. Ependymal distribution. J. Cell Biol. 1965, 26, 99-123.
245. Phillipe, J.M.; Dubois, J.M.; Rouzaire-Dubois, B.; Cartron, P.F.; Vallette, F.; Morel, N. Functional expression of V-ATPases in the plasma membrane of glial cells. Glia 2002, 37, 365-373.
246. Tabernero, A.; Velasco, A.; Granda, B.; Lavado, E.M.; Medina, J.M. Transcytosis of albumin in astrocytes activates the sterol regulatory element-binding protein-1, which promotes the synthesis of the neurotrophic factor oleic acid. J. Biol. Chem. 2002, 277, 4240-4246.
247. Brasnjevic, I.; Steinbusch, H.W.M.; Schmitz, C.; Martinez-Martinez, P.; and the European NanoBioPharmaceutics Research Initiative. Delivery of peptide and protein drugs over the blood-brain barrier. Progr. Neurobiol. 2009, 87, 212-251.
248. Curry, S.; Brick, P.; Franks, N.P. Fatty acid binding to human serum albumin: new insights from crystallographic studies. Biochem. Biophys. Acta 1999, 1441, 131-140.
249. Sugio, S.; Kashima, A.; Mochizuki, S.; Noda, M.; Kobayashi, K. Crystal structure of human serum albumin at 2.5 Å resolution. Protein Eng. 1999, 12, 439-446.
250. Carver, L.A.; Schnitzer, J.E. Caveolae: Mining little caves for new cancer targets. Nat. Rev. 2003, 3, 571-581.
251. Milici, A.J.; Watrous, N.E.; Stukenbrok, H.; Palade, G.E. Transcytosis of albumin in capillary endothelium. J. Cell Biol. 1987, 105, 2603-2612.
252. Ghitescu, L.; Fixman, A.; Simionescu, M.; Simionescu, N. Specific binding sites for albumin restricted to plasmalemmal vesicles of continuous capillary endothelium: receptor-mediated transcytosis. J. Cell Biol. 1986, 102, 1304-1311.
253. Oh, P.; McIntosh, D.P.; Schnitzer, J.E. Dynamin at the neck of caveolae mediates their budding to form transport vesicles by GTP-driven fission from the plasma membrane of endothelium. J. Cell Biol. 1998, 141, 101-114.
254. Schnitzer, J.E.; Oh, P.; McIntosh, D.P. Role of GTP hydrolysis in fission of caveolae directly from plasma membranes. Science 1996, 274, 239-242.
255. Choudhury, A.; Dominguez, M.; Puri, V.; Sharma, D.K.; Narita, K.; Wheatley, C.L.; Marks, D.L.; Pagano, R.E. Rab proteins mediate Golgi transport of caveola-internalized glycosphingolipids and correct lipid trafficking in Niemann-Pick C cells. J. Clin. Invest. 2002, 109, 1541-1550.
256. Conrad, P.A.; Smart, E.J.; Ying, Y.S.; Anderson, R.G.; Bloom, G.S. Caveolin cycles between plasma membrane caveolae and the Golgi complex by microtubule-dependent and microtubuleindependent steps. J. Cell Biol. 1995, 131, 1421-1433.
257. Smart, E.J.; Ying, Y.S.; Conrad, P.A.; Anderson, R.G.W. Caveolin moves from caveolae to the Golgi apparatus in response to cholesterol oxidation. J. Cell Biol. 1994, 127, 1185-1197.
258. Le, P.U.; Nabi, I.R. Distinct caveolae-mediated endocytic pathways target the Golgi apparatus and the endoplasmic reticulum. J. Cell Biol. 2003, 116, 1059-1071.
259. Puri, V.; Watanabe, R.; Singh, R.D.; Dominguez, M.; Brown, J.C.; Wheatley, C.L.; Marks, D.L.; Pagano, R.E. Clathrin dependent and -independent internalization of plasma membrane sphingolipids initiates two Golgi targeting pathways. J. Cell Biol. 2001, 154, 535-547.
260. Kartenbeck, J.; Stukenbrok, H.; Helenius, A. Endocytosis of simian virus 40 into the endoplasmic reticulum. J. Cell Biol. 1989, 109, 2721-2729.
261. Pelkmans, L.; Kartenback, J.; Helenius, A. Caveolar endocytosis of Simian virus 40 reveals a novel two-step vesicular transport pathway to the ER. Nat. Cell Biol. 2001, 3, 473-483.
262. Benlimame, N.; Le, P.U.; Nabi, I.R. Localization of autocrine motility factor receptor to caveolae and clathrin independent internalization of its ligand to smooth endoplasmic reticulum. Mol. Biol. Cell 1998, 9, 1773-1786.
263. Schnitzer, J.E.; Oh, P.; Pinney, E.; Allard, J. Filipin-sensitive caveolae-mediated transport in endothelium: reduced transcytosis, scavenger endocytosis, and capillary permeability of select macromolecules. J. Cell Biol. 1994, 127, 1217-1232.
264. Tran, D.; Carpentier, J.L.; Sawano, F.; Gorden, P.; Orci, L. Ligands internalized through coated or noncoated invaginations follow a common intracellular pathway. Proc. Natl. Acad. Sci. USA 1987, 84, 7957-7961.
265. Schnitzer, J.E. The endothelial cell surface and caveolae in health and disease. In Vascular Endothelium: Physiology, Pathology and Therapeutic Opportunities; Born, G.V.R., Schwartz, C.J., Eds.; Schattauer: Stuttgart, Germany, 1997; pp.77-95.
266. Simionescu, M.; Simionescu, N. Endothelial transport of macromolecules: transcytosis and endocytosis. A look from cell biology. Cell Biol. Rev. 1991, 25, 1-78.
267. Zhu, P.; Chertova, E.; Bess, J. Jr.; Lifson, J.D.; Arthur, L.O.; Liu, J.; Taylor, K.A.; Roux, K.H. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc. Natl. Acad. Sci. USA 2003, 100, 15812-15817.
268. Huang, C-C.; Tang, M.; Zhang, M-Y.; Majeed, S.; Montabana, E.; Stanfield, R.L.; Dimitrov, D.S.; Korber, B.; Sodroski, J.; Wilson, I.A.; Wyatt, R.; Kwong, P.D. Structure of a V3- containing HIV-1 gp120 core. Science 2005, 310, 1025-1028.
269. Liu, J.; Bartesaghi, A.; Borgnia, M.J.; Sapiro, G.; Subramaniam, S. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008, 455, 109-113.
270. Park, E.Y.; Smith, M.J.; Stropp, E.S.; Snapp, K.R.; DiVietro, J.A.; Walker, W.F.; Schmidtke, D.W.; Diamond, S.L.; Lawrence, M.B. Comparison of PSGL-1 microbead and neutrophil rolling: microvillus elongation stabilizes P-selectin bond clusters. Biophys. J. 2002, 82, 1835-1847.
271. Kienberger, F.; Kada, G.; Mueller, H.; Hinterdorfer, P. Single molecule studies of antibodyantigen interaction strength versus intra-molecular antigen stability. J. Mol. Biol. 2005, 347, 597-606.
272. Hinterdorfer, P.; Baumgartner, W.; Gruber, H.J.; Schilcher, K.; Schindler, H. Detection and localization of individual antibody-antigen recognition events by atomic force microscopy. Proc. Natl. Acad. Sci. USA 1996, 93, 3477-3481.
273. Saleh, O.A.; Sohn, L.L. Direct detection of antibody-antigen binding using an on-chip artificial pore. Proc. Natl. Acad. Sci. USA 2003, 100, 820-824.
274. Fritz, J.; Katopodis, A.G.; Kolbinger, F.; Anselmetti, D. Force-mediated kinetics of single Pselectin/ ligand complexes observed by atomic force microscopy. Proc. Natl. Acad. Sci. USA 1998, 95, 12283-12288.
275. Hanley, W.; McCarty, O.; Jadhav, S.; Tseng, Y.; Wirtz, D.; Konstantopoulos, K. Single molecule characterization of P-selectin/ligand binding. J. Biol. Chem. 2003, 278, 10556-10561.
276. Dammer, U.; Popescu, O.; Wagner, P.; Anselmetti, D.; Guntherodt, H.J.; Misevic, G.N. Binding strength between cell adhesion proteoglycans measured by atomic force microscopy. Science 1995, 267, 1173-1175.
277. Popescu, O.; Checiu, I.; Ghergel, P.; Simon, Z.; Misevic, G.N. Quantitative and qualitative approach of glycan-glycan interactions in marine sponges. Biochimie 2003, 85, 181-188.
278. Shao, J-Y.; Hochmuth, R.M. Micropipette suction for measuring piconewton forces of adhesion and tether formation from neutrophil membranes. Biophys. J. 1996, 71, 2892-2901.
279. Waugh, R.E.; Bauserman, R.G. Physical measurements of bilayer-skeletal separation forces. Ann. Biomed. Eng. 1995, 23, 308-321.
280. Dai, J.; Sheetz, M.P. Mechanical properties of neuronal growth cone membrane studied by tether formation with laser optical tweezers. Biophys. J. 1995, 68, 988-996.
281. Hochmuth, R.M.; Shao, J-Y.; Dai, J.; Sheetz, M.P. Deformation and flow of membrane into tethers extracted from neuronal growth cones. Biophys. J. 1996, 70, 358-369.
282. Alon, R.; Hammer, D.A.; Springer, T.A. Lifetime of the P-selectin-carbohydrate bond and its response to tensile force in hydrodynamic flow. Nature 1995, 374, 539-542.
283. Veronese, F.M. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 2001, 22, 405-417.
284. Berry, C.C.; Curtis, A.S.G. Functionalisation of magnetic nanoparticles for applications in biomedicine. J. Phys. D. Appl. Phys. 2003, 36, R198-R206.
285. Geiser, M.; Kreyling, W.G. Deposition and biokinetics of inhaled nanoparticles. Par. Fibre Toxicol. 2010, 7, 2.
286. Chen, W.; Yang, X. Researches on PEG-modified copolymer nanoparticle. Article in Chinese. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2003, 20, 143-147.
287. Brunner, R.; Jensen-Jarolim, E.; Pali-Schöll, I. The ABC of clinical and experimental adjuvants - A brief overview. Immunol. Lett. 2010, 128, 29-35.
288. Frey, A.; Mantis, N.; Kozlowski, P.A.; Quayle, A.J.; Bajardi, A.; Perdomo, J.J.; Robey, F.A.; Neutra, M.R. Immunization of mice with peptomers covalently coupled to aluminum oxide nanoparticles. Vaccine 1998, 17, 3007-3019.
289. Frey, A.; Neutra, M.R.; Robey, F.A. Spatially aligned conjugated composition having a thioether bond linkage. US Patent 6086881, 2000.
290. Schöll, I.; Weissenböck, A.; Förster-Waldl, E.; Untersmayr, E.; Walter, F.; Willheim, M.; Boltz- Nitulescu, G.; Scheiner, O.; Gabor, F.; Jensen-Jarolim, E. Allergen-loaded biodegradable poly(D,L-lactic-co-glycolic) acid nanoparticles down-regulate an ongoing Th2 response in the BALB/c mouse model. Clin. Exp. Aller. 2004, 34, 315-321.
291. Baumeister, H. A novel human expression system for production of higher active biotherapeutics with optimised glycosylation. Pharm. Chem. Biopharm. 2006, 2, 21-24.
292. Baumeister, H.; Goletz, S. Novel glycosylation technologies for the development of biosimilars and biobetters. Innova. Pharma. Technol. 2009, 52-58.
293. Brooks, S.A. Appropriate glycosylation of recombinant proteins for human use: implications of choice of expression system. Mol. Biotechnol. 2004, 28, 241-255.
294. Kawasaki, N.; Itoh, S.; Hashii, N.; Takakura, D.; Qin, Y.; Huang, X.; Yamaguchi, T. The significance of glycosylation analysis in development of biopharmaceuticals. Biol. Pharm. Bull. 2009, 32, 796-800.
295. Stollenwerk, M.M.; Pashkunova-Martic, I.; Kremser, C.; Talasz, H.; Thurner, G.C.; Abdelmoez, A.A.; Wallnöfer, E.A.; Helbok, A.; Neuhauser, E.; Klammsteiner, N.; Klimaschewski, L.; von Guggenberg, E.; Fröhlich, E.; Keppler, B.; Jaschke, W.; Debbage, P. Albumin-based nanoparticles as Magnetic Resonance contrast agents: I. Concept, first syntheses and characterisation. Histochem. Cell Biol. 2010, 133, 375-404.
296. Abdelmoez, A.A.; Thurner, G.C.; Wallnöfer, E.A.; Klammsteiner, N.; Kremser, C.; Talasz, H.; Mrakovcic, M.; Froehlich, E.; Jaschke, W.; Debbage, P. Albumin-based nanoparticles as Magnetic Resonance contrast agents: II. Physicochemical characterization of purified and standardised nanoparticles. Histochem. Cell Biol. 2010, 134, 171-196.
297. Kratz, F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J. Control. Release 2008, 132, 171-183.
298. Peters, T. Jr. All about Albumin. Biochemistry, Genetics, and Medical Applications; Academic Press: San Diego, CA, USA, 1996; p. 432.
299. Duncan, R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2003, 2, 347-360
300. Greco, F.; Vicent, M.J. Polymer-drug conjugates: current status and future trends. Front. Biosci. 2008, 13, 2744-2756.
301. Bharali, D.J.; Khalil, M.; Gurbuz, M.; Simone, T.M.; Mousa, S.A. Nanoparticles and cancer therapy: A concise review with emphasis on dendrimers. Int. J. Nanomed. 2009, 4, 1-7.
302. Duncan, R.; Izzo, L. Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev. 2005, 57, 2215-2237.
303. Lee, C.C.; MacKay, J.A.; Fréchet, J.M.; Szoka, F.C. Designing dendrimers for biological applications. Nat. Biotechnol. 2005, 23, 1517-1526.
304. Moghimi, S.M.; Patel, H.M. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - The concept of tissue specificity. Adv. Drug Deliv. Rev. 1998, 32, 45-60.
305. Senior, J.H. Fate and behaviour of liposomes in vivo: a review of controlling factors. CRC Crit. Rev. Ther. Drug Carrier System 1987, 3, 123-193.
306. Bonté, F.; Hsu, M.J.; Papp, A.; Wu, K.; Regen, S.L.; Juliano, R.L. Interactions of polymerizable phosphatidylcholine vesicles with blood components: relevance to biocompatibility. Biochim. Biophys. Acta 1987, 900, 1-9.
307. Juliano, R.L. Factors controlling the kinetics and tissue distribution of liposomes, microspheres, and emulsions. Adv. Drug Delivery Rev. 1988, 2, 31-54.
308. Chonn, A.; Cullis, P.R.; Devine, D.V. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J. Immunol. 1991, 146, 4234-4241.
309. Chonn, A.; Semple, S.C.; Cullis, P.R. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J. Biol. Chem. 1992, 267, 18759-18765.
310. Patel, H.M. Serum opsonins and liposomes: Their interaction and opsonophagocytosis. Crit. Rev. Ther. Drug Carrier Syst. 1992, 9, 39-90.
311. Dave, J.; Patel, H.M. Differentiation in hepatic and splenic phagocytic activity during reticuloendothelial blockade with cholesterol free and cholesterol rich vesicles. Biochim. Biophys. Acta 1986, 888, 184-190.
312. Liu, D.; Hu, Q.; Song, Y.K. Liposome clearance from blood: different animal species have different mechanisms. Biochim. Biophys. Acta 1995, 1240, 277-284.
313. Torchilin, V.; Trubetskoy, V. Which polymers can make nanoparticulate drug carriers longcirculating? Adv. Drug Deliv. Rev. 1995, 16, 141-155.
314. Wattendorf, U.; Merkle, H.P. PEGylation as a tool for the biomedical engineering of surface modified microparticles. J. Pharm. Sci. 2008, 97, 4655-4669.
315. Lemarchand, C.; Gref, R.; Couvreur, P. Polysaccharide decorated nanoparticles. Eur. J. Pharm. Biopharm. 2004, 58, 327-341.
316. OECD Joint Meeting of the Chemicals Committee. No. 6. List of manufactured nanomaterials and list of endpoints for phase one of the OECD testing programme. In Working Party on Manufactured Nanomaterials (2008) Series on the Safety of Manufactured Nanomaterials. ENV/JM/MONO(2008)13/REV; Available online: www.oecd.org/ehs. For updates see www.oecd.org/env/nanosafety/.